Tweet
Front Immunol
. 2025 Nov 17:16:1655917.
doi: 10.3389/fimmu.2025.1655917. eCollection 2025. Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis
Erika Biegelmeyer 1 , Mariana de Freitas Aguiar 1 , Priscila Dias Cardoso Ribeiro 1 , Ketty Lysie Libardi Lira Machado 2 , Camila Maria Paiva França Telles 3 , Sandra Lúcia Euzébio Ribeiro 3 , Natália Sarzi Sartori 4 , Rodrigo Poubel Vieira de Rezende 5 , Ana Karla Guedes de Melo 6 , Vitor Alves Cruz 7 , Rejane Maria Rodrigues de Abreu Vieira 8 , Adriana Maria Kakehasi 9 , Maria Cecília Dias Corrêa 10 , Valderilio Feijó Azevedo 11 , Olindo Assis Martins-Filho 12 , Flávia Maria Matos Melo Campos Peixoto 1 , Vanessa de Oliveira Magalhães 1 , Maria da Penha Gomes Gouveia 2 , Thaís Evelyn Karnopp 4 , Katia Lino Baptista 5 , Tâmara Santos Melo 6 , Jozelia Rêgo 7 , Adah Sophia Rodrigues Vieira 8 , Anna Carolina Faria Moreira Gomes Tavares 9 , Victória Dornelas Paz Carvalho 10 , Vanessa Peruhype-Magalhães 12 , Laiza Hombre Dias 2 , Raquel Lima de Lima 3 , Kimberly Rossana da Silva Gonçalves 4 , Natália Rodrigues Querido Fortes 5 , Débora Marques Veghini 2 , Jônatas Almeida Amorim 3 , Raiza Casian Tuão 2 , Karina Rosemarie Lallemand Tapia 2 , Cristiane Kayser 1 , Charlles Heldan de Moura Castro 1 , Maressa Barbosa Beloni Lirio 2 , Juliana Bühring 3 , Ricardo Machado Xavier 4 , Andréa Teixeira-Carvalho 12 , Viviane Angelina de Souza 10 , Odirlei André Monticielo 4 , Gilda Aparecida Ferreira 9 , Marcelo de Medeiros Pinheiro 1 , Edgard Torres Dos Reis Neto 1 , Emilia Inoue Sato 1 , Valeria Valim 2 , Gecilmara Salviato Pileggi 1 , Alexandre Wagner Silva de Souza 1
Affiliations
Background/objectives: Patients with systemic vasculitis faced the risk of severe COVID-19 and high mortality during the pandemic. Although SARS-CoV-2 vaccination mitigates these outcomes, vaccine hesitancy persists, and data on immunogenicity and safety in vasculitis is still limited. This study aims to assess response to primary and booster doses of SARS-CoV-2 vaccination in systemic vasculitis.
Methods: This multicenter cohort study including systemic vasculitis included patients from SAFER study (Safety and Efficacy of COVID-19 Vaccines in Rheumatic Diseases). We evaluated serum IgG levels against the SARS-CoV-2 spike protein receptor-binding domain (IgG anti-RBD) at baseline and 28 days post-vaccination, disease activity scores, new cases of COVID-19 infections, and adverse events.
Results: Seventy-three patients with systemic vasculitis were included. Behçet's disease (n=39), Takayasu arteritis (n=15), and antineutrophil cytoplasmic antibody-associated vasculitis (n=14) were the most common vasculitis forms. The majority of the patients had no comorbidities and were in remission. Seventy patients received one, 65 two, and 60 three vaccine doses. ChAdOx1 nCoV-19 (AstraZeneca/Oxford) (n=36) and CoronaVac (Sinovac) (n=25) were primarily the most common vaccines, while BNT162b2 (Pfizer-BioNTech) was usually the booster vaccine. ChAdOx1 nCoV-19 induced higher IgG anti-RBD than CoronaVac after two doses (p=0.002), but this difference disappeared after the booster dose. No differences in vaccine response were noted between heterologous and homologous regimens or vasculitis types. The new cases of COVID-19 (16.9%), hospitalization (1.5%), and mortality (1.5%) rates were relatively low following vaccination. Disease activity remained stable, and adverse events were mostly mild. Only one severe adverse event was observed.
Conclusion: Different SARS-CoV-2 vaccines demonstrated immunogenicity and clinical effectiveness in systemic vasculitis. The three-dose schedule was safe without increasing relapse risk.
Keywords: ANCA-associated vasculitis; Behçet’s disease; COVID-19; SARS-CoV-2 vaccination; Takayasu arteritis; vaccination; vasculitis.
. 2025 Nov 17:16:1655917.
doi: 10.3389/fimmu.2025.1655917. eCollection 2025. Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis
Erika Biegelmeyer 1 , Mariana de Freitas Aguiar 1 , Priscila Dias Cardoso Ribeiro 1 , Ketty Lysie Libardi Lira Machado 2 , Camila Maria Paiva França Telles 3 , Sandra Lúcia Euzébio Ribeiro 3 , Natália Sarzi Sartori 4 , Rodrigo Poubel Vieira de Rezende 5 , Ana Karla Guedes de Melo 6 , Vitor Alves Cruz 7 , Rejane Maria Rodrigues de Abreu Vieira 8 , Adriana Maria Kakehasi 9 , Maria Cecília Dias Corrêa 10 , Valderilio Feijó Azevedo 11 , Olindo Assis Martins-Filho 12 , Flávia Maria Matos Melo Campos Peixoto 1 , Vanessa de Oliveira Magalhães 1 , Maria da Penha Gomes Gouveia 2 , Thaís Evelyn Karnopp 4 , Katia Lino Baptista 5 , Tâmara Santos Melo 6 , Jozelia Rêgo 7 , Adah Sophia Rodrigues Vieira 8 , Anna Carolina Faria Moreira Gomes Tavares 9 , Victória Dornelas Paz Carvalho 10 , Vanessa Peruhype-Magalhães 12 , Laiza Hombre Dias 2 , Raquel Lima de Lima 3 , Kimberly Rossana da Silva Gonçalves 4 , Natália Rodrigues Querido Fortes 5 , Débora Marques Veghini 2 , Jônatas Almeida Amorim 3 , Raiza Casian Tuão 2 , Karina Rosemarie Lallemand Tapia 2 , Cristiane Kayser 1 , Charlles Heldan de Moura Castro 1 , Maressa Barbosa Beloni Lirio 2 , Juliana Bühring 3 , Ricardo Machado Xavier 4 , Andréa Teixeira-Carvalho 12 , Viviane Angelina de Souza 10 , Odirlei André Monticielo 4 , Gilda Aparecida Ferreira 9 , Marcelo de Medeiros Pinheiro 1 , Edgard Torres Dos Reis Neto 1 , Emilia Inoue Sato 1 , Valeria Valim 2 , Gecilmara Salviato Pileggi 1 , Alexandre Wagner Silva de Souza 1
Affiliations
- PMID: 41333456
- PMCID: PMC12665670
- DOI: 10.3389/fimmu.2025.1655917
Background/objectives: Patients with systemic vasculitis faced the risk of severe COVID-19 and high mortality during the pandemic. Although SARS-CoV-2 vaccination mitigates these outcomes, vaccine hesitancy persists, and data on immunogenicity and safety in vasculitis is still limited. This study aims to assess response to primary and booster doses of SARS-CoV-2 vaccination in systemic vasculitis.
Methods: This multicenter cohort study including systemic vasculitis included patients from SAFER study (Safety and Efficacy of COVID-19 Vaccines in Rheumatic Diseases). We evaluated serum IgG levels against the SARS-CoV-2 spike protein receptor-binding domain (IgG anti-RBD) at baseline and 28 days post-vaccination, disease activity scores, new cases of COVID-19 infections, and adverse events.
Results: Seventy-three patients with systemic vasculitis were included. Behçet's disease (n=39), Takayasu arteritis (n=15), and antineutrophil cytoplasmic antibody-associated vasculitis (n=14) were the most common vasculitis forms. The majority of the patients had no comorbidities and were in remission. Seventy patients received one, 65 two, and 60 three vaccine doses. ChAdOx1 nCoV-19 (AstraZeneca/Oxford) (n=36) and CoronaVac (Sinovac) (n=25) were primarily the most common vaccines, while BNT162b2 (Pfizer-BioNTech) was usually the booster vaccine. ChAdOx1 nCoV-19 induced higher IgG anti-RBD than CoronaVac after two doses (p=0.002), but this difference disappeared after the booster dose. No differences in vaccine response were noted between heterologous and homologous regimens or vasculitis types. The new cases of COVID-19 (16.9%), hospitalization (1.5%), and mortality (1.5%) rates were relatively low following vaccination. Disease activity remained stable, and adverse events were mostly mild. Only one severe adverse event was observed.
Conclusion: Different SARS-CoV-2 vaccines demonstrated immunogenicity and clinical effectiveness in systemic vasculitis. The three-dose schedule was safe without increasing relapse risk.
Keywords: ANCA-associated vasculitis; Behçet’s disease; COVID-19; SARS-CoV-2 vaccination; Takayasu arteritis; vaccination; vasculitis.